Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

View:
Post by deadpatient on Jan 05, 2021 4:57pm

CONCERN

This is not behaving like a phase 3 ready stock..... the management team has to be upgraded,to deal with the big boys inthe u.s capital markets........I hate to say it but starting with removing dan would be a good start
Comment by Qtrlbder on Jan 05, 2021 6:56pm
And you are behaving like s basher /shorter....!!!!!!!!!!
Comment by Marky1 on Jan 05, 2021 7:10pm
I think that Dan is doing a fine job! Give Dan, Stern and Dr. Stauffer a huge Thank You! By the end of January, I believe that ATE will be trading closer to its true value Best of luck to all the longs!
Comment by RalphRalph on Jan 05, 2021 9:15pm
To the contrary, I think you could replace Dan with the CEO of most any public biotech company and get at least equal job performance, if not markedly better.  I don't see any special value that he has provided to the company, but I do see numerous instances of poor decision-making.    Truly 'fine' biotech CEOs deliver returns for shareholders (as reflected in stock ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities